Table II.

COVID-19 outcomes in patients with and without asthma

Outcome	Study	City	Asthma group	Nonasthma group	P value∗
Hospitalization	Mahdavinia et al18	Chicago, USA	73 of 241	224 of 694	.65
	Chhiba et al19	Chicago, USA	115 of 220	738 of 1306	.242
Length of hospital stay (d)	Lovinsky-Desir et al20	New York City, USA	Median: 6, IQR: 9	Median: 5, IQR: 9	.25
	Mahdavinia et al18	Chicago, USA	Mean: 8.36, SD: 6.02	Mean: 7.81, SD: 5.19	.25
	Barroso et al21	Madrid, Spain	Mean: 9.72, SD: 8.14	Mean: 10.9, SD: 9.67	NS
Acute respiratory distress syndrome	Mahdavinia et al18	Chicago, USA	22 of 241	65 of 694	.92
	Song et al22	Wuhan, China	1 of 22	128 of 918	.35
Severe cases	Song et al22	Wuhan, China	1 of 22	229 of 918	.02
ICU admission	Beurnier et al23	Paris, France	11 of 37	33 of 75	.21
	Barroso et al21	Madrid, Spain	2 of 11	30 of 178	>.99
Mechanical ventilation/ intubation	Lovinsky-Desir et al20	New York City, USA	34 of 163	231 of 1135	.92
	Mahdavinia et al18	Chicago, USA	23 of 241	56 of 694	.35
	Beurnier et al23	Paris, France	6 of 37	15 of 75	.82
	Song et al22	Wuhan, China	1 of 22	141 of 918	.23
Death	Lovinsky-Desir et al20	New York City, USA	9 of 163	101 of 1135	.18
	Mahdavinia et al18	Chicago, USA	2 of 241	16 of 694	.22
	Beurnier et al23	Paris, France	3 of 37	11 of 75	.38
	Song et al22	Wuhan, China	1 of 22	148 of 918	.23
	Chhiba et al19	Chicago, USA	8 of 220	64 of 1306	.413
	Barroso et al21	Madrid, Spain	2 of 11	22 of 178	.63

IQR, Interquartile range; NS, not significant.

^∗P values provided in the article are shown in regular type, while P values calculated with Fisher exact tests or χ² tests are shown in italic type.